Plain-English translation of NCT06767436 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of trastuzumab-deruxtecan, a targeted cancer medication designed for advanced stomach cancer. Researchers want to understand how well this medication works and how safe it is when used in everyday clinical practice, rather than just in controlled research settings. The study will follow patients who have already started or are planning to start this treatment.
While this medication has shown promise in clinical trials, researchers need to understand how it performs in real patients across different hospitals and situations. This information helps doctors make better treatment decisions and understand which patients benefit most from this therapy.
You likely qualify if…
You likely don't qualify if…
Researchers will gather information from your medical records about your treatment with this medication and how your cancer responds. If you are currently receiving or planning to receive this treatment, this will continue through March 2027. The study does not require you to attend additional appointments or receive different treatment — it simply involves collecting data that is already part of your regular cancer care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
South Korea
Sponsor
Yonsei University
Enrollment target
~300 participants
Started
November 2024
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
minkyu Jung
Yonsei Cencer center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.